Solara Active Pharma Sciences Ltd
Solara Active Pharma Sciences Q2 FY27 Consolidated Profit Rs. 28.46 Crores
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 16 Oct 2026, 01:36 PM IST · BSE ID: c67e5f02-2ea8-43f9-a54f-c924c81dcb68
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its latest financial performance, showing Rs. 417.34 Crores in revenue and Rs. 28.46 Crores in profit.
🤖 AI Summary
- Board approved unaudited consolidated financial results for the quarter and half year ended September 30, 2026.
- Consolidated Revenue from operations was Rs. 417.34 Crores for the quarter ended September 30, 2026.
- Consolidated Profit for the period reached Rs. 28.46 Crores for the quarter ended September 30, 2026.
- Consolidated Basic Earnings Per Share was Rs. 5.92 for the quarter ended September 30, 2026.
- The review report was issued by M/s. Deloitte Haskins & Sells, Chartered Accountants.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from operations (Q2 FY27)
Rs. 417.34 Crores
33.11%
Consolidated Revenue from operations (Q2 FY26)
Rs. 313.54 Crores
Consolidated Profit for the period (Q2 FY27)
Rs. 28.46 Crores
Not comparable — previous period was a loss
Consolidated Profit for the period (Q2 FY26)
Rs. (10.10) Crores
Basic Earnings per equity share (Q2 FY27)
Rs. 5.92
Not comparable — previous period was a loss
🏢 How This Affects the Company
The company reported an increase in revenue from operations to Rs. 417.34 Crores for Q2 FY27, compared to Rs. 313.54 Crores in the corresponding prior period.
Consolidated Profit for the period improved to Rs. 28.46 Crores in Q2 FY27 from a loss of Rs. 10.10 Crores in Q2 FY26. Earnings Per Share also increased to Rs. 5.92 per share.
The cost of materials consumed increased to Rs. 217.80 Crores in Q2 FY27 from Rs. 149.69 Crores in Q2 FY26, indicating higher production or input costs aligned with revenue growth.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results disclosure.
👤
Who Is Affected
All equity shareholders are affected by the company's financial performance, with Basic EPS rising to Rs. 5.92 per share for Q2 FY27.
🔍
Management Signal
The approval of the unaudited financial results and their public disclosure indicates management's adherence to regulatory reporting standards and transparency.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q3 FY27 results — monitor continued revenue growth and profitability.
Update on subsidiaries — check for auditor review status of the unreviewed subsidiaries.
Capital expenditure plans — track any announcements related to capacity expansion.
MEDIUM RISK
Financial results of two subsidiaries were not reviewed by auditors.
💡 Investor Takeaway
Solara Active Pharma Sciences reported Q2 FY27 consolidated revenue from operations of Rs. 417.34 Crores, a 33.11% increase from Rs. 313.54 Crores in Q2 FY26. Consolidated profit for the period was Rs. 28.46 Crores, compared to a loss of Rs. 10.10 Crores in the prior year period.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated Revenue from operations increased to Rs. 417.34 Crores in Q2 FY27 from Rs. 313.54 Crores in Q2 FY26, a 33.11% YoY growth.
- Consolidated Profit for the period improved to Rs. 28.46 Crores in Q2 FY27 from a loss of Rs. 10.10 Crores in Q2 FY26.
⚠️ Concerns
- The consolidated unaudited financial results include interim financial information of 2 subsidiaries not reviewed by their auditors, reflecting Rs. 6.75 Crores total assets.
- These unreviewed subsidiaries reported total net loss after tax of Rs. 0.02 Crores for Q2 FY27.
📅 Company Track Record
Solara Active Pharma Sciences reported a consolidated net profit of Rs. 16.31 Crores in Q1 FY27, representing a 55.04% YoY increase. In Q4 FY26, the company's Base Business revenue increased by 36% YoY, though its Ibuprofen business reported a negative EBITDA of INR 179 million.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What were Solara Active Pharma Sciences' consolidated revenues in Q2 FY27?
Solara Active Pharma Sciences reported consolidated Revenue from operations of Rs. 417.34 Crores for the quarter ended September 30, 2026.
What was Solara Active Pharma Sciences' consolidated net profit for Q2 FY27?
The consolidated Profit for the period for Solara Active Pharma Sciences was Rs. 28.46 Crores for the quarter ended September 30, 2026.
How did Solara Active Pharma Sciences' Q2 FY27 revenue compare to the previous year?
Consolidated Revenue from operations in Q2 FY27 was Rs. 417.34 Crores, compared to Rs. 313.54 Crores in the corresponding quarter ended September 30, 2025.
What was Solara Active Pharma Sciences' Basic EPS for Q2 FY27?
Solara Active Pharma Sciences' Basic Earnings per equity share (face value of Rs. 10/-each) was Rs. 5.92 for the quarter ended September 30, 2026.
Questions based on this BSE filing only. For information purposes.